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Abstract−Conscious sedation procedures require sedation and 
analgesia sufficient for the particular procedure but not so deep 
as to cause apnea.  Fast acting sedatives such as Propofol are 
increasingly used in these procedures although they cause more 
severe respiratory depression than more traditional sedatives 
such as Midazolam.  A method was devised to maintain 
respiration during conscious sedation by administering inspired 
CO2 as a respiratory stimulant to offset the reduced respiratory 
drive caused by Propofol. A computer model was implemented 
which predicts respiratory depression caused by Propofol 
administration.  Simulations of common dosing regimens were 
performed with and without inspired CO2.  For all dosing 
regimens, adding inspired CO2 prevented the respiration from 
falling as much as the control and respiration returned to 
baseline within 4 to 6 minutes.  Administering inspired CO2 
during conscious sedation seems to be an effective way to 
prevent respiratory depression according to the best available 
numerical model. 
 
Keywords−Rebreathing, Conscious sedation, Procedural 
sedation, Carbon Dioxide, Computer modeling, Propofol. 
 
 
INTRODUCTION 
 
Conscious sedation is light sedation where the patient 
maintains spontaneous breathing and is used during such 
common procedures include endoscopy, cardioversion, 
defibrillator implantation, tonsillectomy and dental 
surgery.12,22  Surgical procedures requiring conscious 
sedation are very common, accounting for an estimated 
200 million surgical procedures per year in the U.S.11  
 The economics of procedures requiring conscious 
sedation make it impossible to have an anesthesiologist 
attending to the drug administration.  In many cases, a 
nurse or even the physician performing the procedure 
must act as the sedationist.  Over-sedation is a common 
leading factor causing cardiopulmonary problems during 
and after the procedure.7  Respiratory problems like apnea 
and respiratory depression account for up to 70% of all 
adverse events occurring during procedures requiring 
conscious sedation.10   
While respiratory complications account for most 
adverse events during conscious sedation, many of the 
sedationists are not well trained to respond to adverse 
events.12,22,7,10  The American Society for Gastrointestinal 
Endoscopy reports that only 76% of its endoscopists are 
certified in Basic Life Support and only 30.2% of them 
are certified in Advanced Cardiopulmonary Life Support 
with the ability to perform intubation.12  These figures 
indicate the need to insure safety from respiratory 
depression for patients undergoing conscious sedation.   
Arterial CO2 provides the fast feedback control of 
respiration to maintain gas exchange equal to metabolic 
production.  When a respiratory depressant is 
administered, CO2 builds up and the body responds by 
increasing respiratory drive.3,5  Fast-onset anesthetics 
cause more severe respiratory depression because the 
body has less time to build up CO2 to counter the 
respiratory depression of the drug.2,5,14  Thus, these drugs, 
while good for patient turn around, pose a greater risk of 
respiratory depression and apnea.2,5,14  Fast acting drugs, 
large patient variability and a small therapeutic window 
between sufficient sedation and apnea make it difficult for 
sedationists to titrate to the needed level of sedation 
without overshooting into apnea.2,5,14  
There is a need to widen the therapeutic window for 
conscious sedation by increasing the range of safe drug 
concentration between sufficient sedation and over 
sedation.  I propose to accomplish this by elevating the 
patients arterial CO2 by administering a low concentration 
of inspired CO2 during drug administration effectively 
increasing respiratory drive to counter the depressant 
effect of the drug.  This article will describe the 
application of a numerical model as a proof of concept for 
the respiration protection system. 
  
 
MATERIALS AND METHODS 
 
Respiratory Simulator 
 
 Bouillon et al developed and validated a respiratory 
model which describes the non-steady state changes in 
alveolar ventilation caused by Propofol.5  Propofol is a 
fast acting sedative-hypnotic with a half life of 2-4 
minutes and a substantial respiratory depressant effect.21,6  
The Bouillon model takes effect site Propofol 
concentration as an input and calculates respiratory 
depression based on a sigmoid Emax model often used to 
describe Propofol effect.5  Bouillon derived and validated 
the model parameters with a volunteer study.  See the 
appendix for a description of the model derivation as well 
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as model parameters.  Bouillon makes a simplification in 
his derivation by assuming that inspired CO2 will be close 
to zero for spontaneously breathing patients.  I modified 
Bouillon's model to account for inspired CO2 by 
modifying the term representing the gradient across the 
blood pulmonary barrier to be the difference between 
arterial and inspired partial pressures of CO2, giving the 
following expression: 
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The first term of this expression represents metabolic 
production of CO2.  Note that this model takes into 
account the maximum 30% expected decrease in CO2 
production at full drug effect.  The second term represents 
clearance of CO2 from the body by the lungs. 
 The above model was implemented as an iterative 
simulator model in Matlab.  See the description of the 
model derivation in the appendix for other expressions 
and parameters necessary to assemble this numeric model.   
 
Inspired CO2 Controller 
 
 Equation 2 represents the proportional integral 
derivative (PID) controller which was programmed into 
Matlab to control the inspired CO2 based on minute 
ventilation. This controller takes alveolar ventilation as an 
input and uses baseline alveolar ventilation (6.5L/min in 
my simulations) as the set point.  The integral and 
derivative gains are expressed as fractions of the partial 
gain to facilitate manual tuning.  PID gains were varied 
until the system responded well for a step change in effect 
site concentration.  The controller was made to limit 
inspired carbon dioxide below 10%. 
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Simulation Case Study 
 
Blayney et al. used a target controlled infusion pump to 
find the optimal concentration of Propofol required for 
exodontia in 300 adult patients.4  Their results indicate 
2.1µg/ml to be the mean effect site concentration resulting 
in sufficient sedation without respiratory depression.  
Taking 2.1µg/ml as a target effect site concentration, I 
devised 3 dosing regimens that could easily be 
implemented with a simple infusion pump.  Figure 1 
shows that the first regimen reaches the effect site 
concentration of 2.1µg/ml in 1.5 minutes with an initial 
bolus, then maintains that conc. within 0.1µg/ml.  The 
second and third regimens reach 2.1µg/ml in 2.5 minutes 
and 5 minutes respectively through infusions, then 
maintain the effect site conc. within 0.1µg/ml.   
 
 
 
 
FIGURE 1. Effect site concentration traces used as a case 
study to tune and test the inspired CO2 PID controller.  These 
traces serve as the test input to the simulator. 
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The effect site traces in Figure 1 represent the range of 
time that a sedationist may take to bring their patient to 
the level of sedation necessary for exodontia.   
The faster infusion is likely to cause more severe 
respiratory depression than the slow infusion.  These 
effect site traces were fed into the computer simulator and 
the non-steady state result in respiratory depression was 
calculated.  The PID gains were adjusted until the system 
responded well to all three regimens. 
 
 
RESULTS 
 
Validation 
 
To validate that my simulator function describes 
Bouillon’s results, I manually entered the same effect site 
concentration profiles as in his publication and ran my 
model with inspired CO2 set to zero.  Figure 2 gives the 
results of my implementation of Bouillon's model.  These 
time values match those reported by Bouillon withing 2% 
of the value at each point indicating that the computer 
model is accurate.   
 
Simulation Case Study 
 
 The PID gains that caused the PID controller to respond 
with minimal overshoot to all three dosing regimens are 
recorded in Table 1 along with  other parameters of the 
simulation. 
 Figure 3 gives the response of the controller and 
respiratory model to the changes in effect site 
concentration of Figure 1 both with and without inspired 
CO2.  The depth of the initial respiratory depression is 
dependent on the rate of infusion with the faster infusion 
causing the greatest depression as anticipated.   
 
 
FIGURE 2.  Results of my implementation of Bouillon’s 
model, PaCO2 and alveolar ventilation resulting form a rapid 
bolus and slow infusion of Propofol. Compare to Figure 5 in 
Bouillon.5 
TABLE 1.  PID gains and other simulation parameters. 
P a r a m e t e r V a lu e
K p  = 3 0 0
K i  = 0 . 0 0 5
K d  = 6 . 5
V a lv ( 0 )  =  4 1  m m H g
P e c C O 2 ( 0 )  = 4 1  m m H g
 
 
 
Inspired CO2 prevents the initial drop in ventilation from 
being as extreme as the control with the greatest 
prevention observed for the slower infusion.  The PID 
controller is able to return the ventilation to its baseline 
value in 4 to 7 minutes in contrast to the control which 
doesn't return to baseline but equilibrates at about 68% of 
normal ventilation.  As expected, inspired CO2 had the 
least significant effect on preventing the initial depression 
for the bolus regimen, giving a mere 17% increase from 
the minimum alveolar ventilation compared to the control.  
Improvement is much more significant for the rapid and 
slow infusion regimens, giving 72% and 89% increases 
from the minimum alveolar ventilation without CO2 
respectively.   The equilibrium arterial CO2 was 48mmHg 
for the control and 53mmHg with inspired CO2. 
To reduce the initial drop in alveolar ventilation for the 
bolus regimen, a second simulation was performed with  
inspired CO2 administered for 2.5 minutes before the drug 
is administered allowing more time to increase arterial 
CO2.  Target ventilation is set to 1.75x baseline for this 
2.5 minute period.  After drug administration the target 
returns to baseline.  Figure 4 compares ventilation with 
and without the period of pre-inspired CO2.  With the 
period of pre-elevation of arterial CO2, ventilation quickly 
elevates to twice it's resting value.   
 
 
 
 
FIGURE 3. Alveolar ventilation depression due to a bolus, 
rapid infusion and slow infusion of Propofol without inspired 
carbon dioxide (dashed lines) and with inspired carbon 
dioxide (solid lines). 
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FIGURE 4.  Alveolar ventilation depression due to a bolus 
of Propofol without inspired carbon dioxide (dashed lines) 
and with a period of inspired carbon dioxide both before and 
after drug administration (solid lines). 
 
Once the bolus is administered ventilation drops to 75% 
of baseline then returns to baseline within 5 minutes.  
This period of pre-elevation allows ventilation to remain 
approximately 30% closer to normal when compared to 
the case where inspired CO2  is given only after the bolus 
is administered. 
 
 
DISCUSSION 
  
Respiratory Control 
 
Respiratory drive, or desire to breath, is a function of 
several factors including CO2 concentration in the 
inspired air, CO2 concentrations in the venous and arterial 
plasma, metabolic production of CO2, concentration of 
CO2 in the respiratory center, drug concentrations 
affecting respiratory drive and the apparent volume of 
distribution of CO2 in the body.9,18  
To predict how a subject will respond to changes in 
inspired CO2, this complex system requires a numerical 
model accounting for drug dynamics and CO2 kinetics 
and dynamics.  A computer based numerical model is 
capable of simulating this system for a realistic sedation 
protocol and can estimate the effect of inspired CO2 on 
patients.  Such a model allows development and 
adjustment of a system for administering inspired CO2 to 
maintain respiration during conscious sedation without 
endangering patients. 
The need to insure patient safety from respiratory 
depression during conscious sedation is augmented by the 
recently increased use of fast acting and potent anesthetic 
drugs such as Propofol.  Propofol, while indicated only 
for use by anesthesiologists, is finding more use by non-
anesthesiologists in physicians offices and ambulatory 
centers because of their rapid onset time and short half 
life.15,16   Titrating sedation without causing apnea is 
complicated by the wide variability of drug sensitivity 
found in the population.  A regimen that is safe for the 
drug tolerant portion of the population may cause nearly 
instant apnea in the drug sensitive population.14,1   
 
Implications of Results 
 
The simulation presented  above indicates that 
respiratory depression may be reduced by feedback 
controlled inspired CO2.  If the inspired CO2 
administration begins when the drug is administered, the 
initial drop is reduced but only slightly for a bolus or a 
fast infusion.  However, the steady-state respiratory 
depression is eliminated within 7 minutes.  Preventing the 
steady state depression has little clinical value.  The utility 
of this technique comes in it's ability to protect drug 
sensitive patients from becoming apneic.  This equates to 
the ability of the technique to prevent the initial 
depression which is more severe than that of steady state.  
To reduce this initial drop, I employed the technique of 
administering CO2 before the drug administration.  This 
simulation was done for the bolus dose because the initial 
drop is proportional to the rate of drug infusion.  Inspired 
CO2 administered after the bolus gives a 10% reduction in 
the initial drop.  Starting the CO2 controller 2.5 minutes 
before the bolus gives a 40% reduction in the initial drop.  
This is a substantial improvement.  It means that a drug 
sensitive patient would have to be about 30% more 
sensitive to the drug to become apneic due to this bolus 
while receiving inspired CO2 starting 2.5 minutes before 
the drug administration. 
One trade-off of pre-inspired CO2 is that it causes an 
extra 2.5 minutes that the physician must wait before 
starting.  Another way to look at the technique is that 
inspired CO2  allows the physician to give faster infusions 
without increasing the risk of apnea.  The 2.5 minute 
period makes the technique less attractive from this 
viewpoint.  However,  the ability to administer the drug 
more quickly may make up for the extra 2.5 minutes 
while increasing safety.  
 
Limitations and Future Investigation 
 
Reported model predictions are only as robust as the 
models ability to emulate the real respiratory control 
system.  As the respiratory control system is much more 
complex than the simple numerical model employed, its 
predictions are limited.  Bouillon selected a sigmoid 
Emax model to determine the respiratory effect due to 
Propofol, which asymptotically approaches full effect 
(apnea) as drug concentration increases.  This means that 
the model will never show the respiration stopping 
regardless of how high the drug concentration goes.  
 Bouillon expressed that the model responds well for the 
concentration ranges they used (<3µg/ml) but it shouldn’t 
be employed out of that range.  In a study of 20 
volunteers, Lee et al. found that 11 of the 20 subjects 
 Inspired Carbon Dioxide  
  
         5 
 
became apneic below an effect site concentration of 
4.0µg/ml.13  The Bouillon model predicts that a subject 
will be breathing at 18% of baseline at this concentration.  
This limitation prevented us from modeling a realistic 
Propofol regimen that would cause apnea, to test with 
inspired CO2.   
In the clinic, patients vary greatly in drug sensitivity 
causing a wide range in the extent of respiratory 
depression caused by standard dosing regimens for 
conscious sedation12,22,11.  Some drug sensitive patients 
become apneic or close to apneic after receiving dosing 
regimens commonly employed and considered safe for a 
particular procedure.  This variability in response to 
anesthetic drugs that I expect to see in the clinical setting 
will allow us to observe the benefit of controlling inspired 
CO2 for a spectrum of respiratory depression.  I expect to 
see that range of respiratory depressions reduced by the 
inspired CO2.   Volunteer studies need to be performed to 
tune the PID controller on actual subjects.  A mask and 
computer controlled CO2 administration device must be 
developed to do these studies.  Finally, a production 
prototype must be made and clinically tested before a 
viable product can be made available. 
In conclusion, this study has simulated the ability of 
inspired CO2 to act as a respiratory stimulant during 
conscious sedation.  The simulation indicated that 
respiratory depression can be substantially reduced 
according to the best available numerical model.  
Volunteer and clinical studies should be done to develope 
a clinically viable protective device for conscious 
sedation. 
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APPENDIX 
 
Using conservation of mass, Bouillon derives an 
expression describing the change in arterial CO2 as a 
function of alveolar ventilation5.   
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Bouillon then uses a sigmoid Emax model to describe the 
ventilatory depressant effect of Propofol as a function of 
Propofol effect site concentration and CO2 effect site 
concentration. 
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Equation four is substituted into equation three replacing 
Valv(t).  Since Propofol is known to decrease carbon 
dioxide production by up to 30%, Bouillon introduces 
another term to correct for metabolic production of CO2 
using a negative sigmoid Emax model to vary CO2 
production between baseline at zero drug effect, and 70% 
baseline at full drug effect. 
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The effect site concentration of carbon dioxide is 
calculated as a single compartment first order transfer 
from plasma to the effect site as follows: 
 
( ) )6(222,02 PecCOPaCOkPecCOdt
d
COe −∗=  
     
 
where ke0,CO2 is the first order rate constant for diffusion 
of CO2 in and out of the effect site.  Bouillon determined 
parameters for this model for 10 volunteers and reported 
the values as a set of typical values with standard error.  
Bouillon also reports a typical value for the CO2 
elimination constant which is used in calculating VdCO2 
as follows: 
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TABLE 2. Parameters used for the respiratory model.6 
Parameter Typical Value
KeoCO2 , (1/min) 0.95
F ,(-) 4.37
Valv(0) , (L/min) 6.45
PaCO2(0) , (mmHg) 40.9
KelCO2 , (1/min) 0.11
C50 , (ug/ml) 1.33
gamma , (-) 1.68
 
 
where kelCO2 is the first order elimination constant of CO2 
at baseline. Bouillon reports the model parameters as 
recorded in table two. 
Bouillon estimated PaCO2 from end-expiratory CO2 for 
each subject.  I communicated with Bouillon to insure that 
the parameters that I used and my understanding of the 
model were correct.  For more specific details about this 
model, see Bouillon’s publication sited above. 
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